Literature DB >> 23587139

From soluble aβ to progressive aβ aggregation: could prion-like templated misfolding play a role?

Yvonne S Eisele1.   

Abstract

Accumulation, aggregation and deposition of Aβ peptides are pathological hallmarks in the brains of individuals affected by Alzheimer's disease (AD) or by cerebral β-amyloid angiopathy (Aβ-CAA). While Aβ is a peptide of yet largely unknown function, it is constantly produced in the human brain where it normally remains in a soluble state. However, Aβ peptides are aggregation prone by their intrinsic ability to adopt alternative conformations rich in β-sheet structure that aggregate into oligomeric as well as fibrillar formations. This transition from soluble to aggregated state has been hypothesized to initiate the pathological cascade and is therefore subject to intensive research. Mounting evidence suggests prion-like templated misfolding as the biochemical phenomenon responsible for promoting progressive Aβ aggregation. Here, we review studies in vitro and in vivo that suggest that cerebral Aβ aggregation may indeed progress via prion-like templated misfolding. The implications of these findings are discussed with respect to understanding initiation and progression of the disease and to developing therapeutics.
© 2013 German Center for Neurodegenerative Diseases (DENE); Brain Pathology © 2013 International Society of Neuropathology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23587139     DOI: 10.1111/bpa.12049

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  15 in total

Review 1.  Amyloid fibril polymorphism: a challenge for molecular imaging and therapy.

Authors:  M Fändrich; S Nyström; K P R Nilsson; A Böckmann; H LeVine; P Hammarström
Journal:  J Intern Med       Date:  2018-02-19       Impact factor: 8.989

Review 2.  Tau acts as a mediator for Alzheimer's disease-related synaptic deficits.

Authors:  Dezhi Liao; Eric C Miller; Peter J Teravskis
Journal:  Eur J Neurosci       Date:  2014-04       Impact factor: 3.386

3.  Resolution exchange with tunneling for enhanced sampling of protein landscapes.

Authors:  Fatih Yasar; Alan J Ray; Ulrich H E Hansmann
Journal:  Phys Rev E       Date:  2022-07       Impact factor: 2.707

4.  Isotope-labeled amyloid-β does not transmit to the brain in a prion-like manner after peripheral administration.

Authors:  Mirjam Brackhan; Giulio Calza; Kristiina Lundgren; Pablo Bascuñana; Thomas Brüning; Rabah Soliymani; Rakesh Kumar; Axel Abelein; Marc Baumann; Maciej Lalowski; Jens Pahnke
Journal:  EMBO Rep       Date:  2022-05-27       Impact factor: 9.071

5.  Mutations and seeding of amylin fibril-like oligomers.

Authors:  Nathan A Bernhardt; Workalemahu M Berhanu; Ulrich H E Hansmann
Journal:  J Phys Chem B       Date:  2013-12-02       Impact factor: 2.991

Review 6.  Targeting protein aggregation for the treatment of degenerative diseases.

Authors:  Yvonne S Eisele; Cecilia Monteiro; Colleen Fearns; Sandra E Encalada; R Luke Wiseman; Evan T Powers; Jeffery W Kelly
Journal:  Nat Rev Drug Discov       Date:  2015-09-04       Impact factor: 84.694

7.  pH-Driven Polymorphism of Insulin Amyloid-Like Fibrils.

Authors:  Tomas Sneideris; Domantas Darguzis; Akvile Botyriute; Martynas Grigaliunas; Roland Winter; Vytautas Smirnovas
Journal:  PLoS One       Date:  2015-08-27       Impact factor: 3.240

8.  Polymorphism of amyloid-like fibrils can be defined by the concentration of seeds.

Authors:  Tomas Sneideris; Katažyna Milto; Vytautas Smirnovas
Journal:  PeerJ       Date:  2015-08-20       Impact factor: 2.984

9.  Gain-of-function mutations in the ALS8 causative gene VAPB have detrimental effects on neurons and muscles.

Authors:  Mario Sanhueza; Luigi Zechini; Trudy Gillespie; Giuseppa Pennetta
Journal:  Biol Open       Date:  2014-01-15       Impact factor: 2.422

10.  Effects of several quinones on insulin aggregation.

Authors:  Hao Gong; Zihao He; Anlin Peng; Xin Zhang; Biao Cheng; Yue Sun; Ling Zheng; Kun Huang
Journal:  Sci Rep       Date:  2014-07-10       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.